|Bid||66.91 x 900|
|Ask||67.00 x 900|
|Day's Range||62.76 - 67.03|
|52 Week Range||43.90 - 100.77|
|Beta (5Y Monthly)||1.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 19, 2024 - Feb 23, 2024|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||92.69|
Subscribe to Yahoo Finance Plus to view Fair Value for EXAS
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTSX returned -7.98%, Advisor Class fund APDSX posted a return of -7.96%, and Institutional Class fund APHSX returned -7.97%, compared to a […]
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present new data and study results across its Precision Oncology and hereditary cancer platforms at the 2023 annual San Antonio Breast Cancer Symposium (SABCS).